Loading...

Evelo Biosciences, Inc.

EVLO•NASDAQ
HealthcareBiotechnology
$0.001
$-0.00(-75.00%)

Evelo Biosciences, Inc. (EVLO) Stock Overview

Explore Evelo Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for EVLOStats details for EVLO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for EVLOAnalyst Recommendations details for EVLO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

CEO

Mr. Craig R. Jalbert CIRA

Employees

66

Headquarters

620 Memorial Drive, Cambridge, MA

Founded

2018

Frequently Asked Questions